CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and...
CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and...
CytomX Therapeutics的股價走高，此前該公司公佈了第一季度財務業績好於預期，並公佈了正在進行的 CX-904 1a 期劑量升級臨床研究的初步數據，顯示出良好的安全性，而且...
CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and Confirmed Anti-cancer Activity.
CytomX Therapeutics的股價走高，此前該公司公佈了第一季度財務業績好於預期，並公佈了正在進行的 CX-904 1a期劑量升級臨床研究的初步數據，顯示出良好的安全狀況和證實的抗癌活性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。